NCT02252042 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 247
- group Id
- BG001
- value
- 248
- group Id
- BG002
- value
- 495
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received standard treatment of either methotrexate 40 mg/m\^2 IV (could be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m\^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
- id
- BG001
- title
- Standard Treatment
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.8
- value
- 60.3
- group Id
- BG001
- spread
- 8.6
- value
- 60.2
- group Id
- BG002
- spread
- 9.2
- value
- 60.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 83
- title
- Female
- measurements
- group Id
- BG000
- value
- 207
- group Id
- BG001
- value
- 205
- group Id
- BG002
- value
- 412
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 33
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 182
- group Id
- BG001
- value
- 195
- group Id
- BG002
- value
- 377
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 41
- group Id
- BG002
- value
- 85
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 31
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 206
- group Id
- BG001
- value
- 207
- group Id
- BG002
- value
- 413
- title
- White
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 32
- title
- Unknown or Not Reported
- description
- The race of participants is presented.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 103
- group Id
- BG001
- value
- 93
- group Id
- BG002
- value
- 196
- title
- TPS = 0%
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 87
- group Id
- BG002
- value
- 166
- title
- 1% ≤ TPS <50%
- measurements
- group Id
- BG000
- value
- 64
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 129
- title
- TPS ≥ 50%
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Missing
- description
- Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Participants with a TPS ≥50% were classified as PD-L1 strongly positive and participants with a TPS \<50% were classified as not strongly positive.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Programmed Cell Death-Ligand 1 (PD-L1) Expression Level: Tumor Proportion Score (TPS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 139
- title
- EGOG PS=0
- measurements
- group Id
- BG000
- value
- 176
- group Id
- BG001
- value
- 179
- group Id
- BG002
- value
- 355
- title
- ECOG PS=1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- ECOG PS=2
- description
- Participants were assessed for ECOG PS: Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature; Grade 2: Ambulatory \& capable of all selfcare but unable to carry out any work activities, up \& about more than 50% of waking hours; Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled, cannot carry on any selfcare, totally confined to bed or chair or Grade 5: Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 118
- title
- Positive HPV Status
- measurements
- group Id
- BG000
- value
- 186
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 377
- title
- Negative HPV Status
- description
- Participants were assessed for the presence or absence of HPV in their tumors.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Human Papillomavirus (HPV) Tumor Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 50
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 104
- title
- PD-L1 CPS <1
- measurements
- group Id
- BG000
- value
- 196
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 387
- title
- PD-L1 CPS ≥1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Missing
- description
- Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Participants with a CPS ≥1 were classified as PD-L1 positive and participants with a CPS \<1 were classified as PD-L1 negative.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- PD-L1 Combined Positive Score (CPS) Status
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 247
- group Id
- BG001
- value
- 248
- group Id
- BG002
- value
- 495
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received standard treatment of either methotrexate 40 mg/m\^2 IV (could be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m\^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
- id
- BG001
- title
- Standard Treatment
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.8
- value
- 60.3
- group Id
- BG001
- spread
- 8.6
- value
- 60.2
- group Id
- BG002
- spread
- 9.2
- value
- 60.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 83
- title
- Female
- measurements
- group Id
- BG000
- value
- 207
- group Id
- BG001
- value
- 205
- group Id
- BG002
- value
- 412
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 33
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 182
- group Id
- BG001
- value
- 195
- group Id
- BG002
- value
- 377
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 41
- group Id
- BG002
- value
- 85
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 31
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 206
- group Id
- BG001
- value
- 207
- group Id
- BG002
- value
- 413
- title
- White
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 32
- title
- Unknown or Not Reported
- description
- The race of participants is presented.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 103
- group Id
- BG001
- value
- 93
- group Id
- BG002
- value
- 196
- title
- TPS = 0%
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 87
- group Id
- BG002
- value
- 166
- title
- 1% ≤ TPS <50%
- measurements
- group Id
- BG000
- value
- 64
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 129
- title
- TPS ≥ 50%
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Missing
- description
- Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Participants with a TPS ≥50% were classified as PD-L1 strongly positive and participants with a TPS \<50% were classified as not strongly positive.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Programmed Cell Death-Ligand 1 (PD-L1) Expression Level: Tumor Proportion Score (TPS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 139
- title
- EGOG PS=0
- measurements
- group Id
- BG000
- value
- 176
- group Id
- BG001
- value
- 179
- group Id
- BG002
- value
- 355
- title
- ECOG PS=1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- ECOG PS=2
- description
- Participants were assessed for ECOG PS: Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature; Grade 2: Ambulatory \& capable of all selfcare but unable to carry out any work activities, up \& about more than 50% of waking hours; Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled, cannot carry on any selfcare, totally confined to bed or chair or Grade 5: Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 118
- title
- Positive HPV Status
- measurements
- group Id
- BG000
- value
- 186
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 377
- title
- Negative HPV Status
- description
- Participants were assessed for the presence or absence of HPV in their tumors.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Human Papillomavirus (HPV) Tumor Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 50
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 104
- title
- PD-L1 CPS <1
- measurements
- group Id
- BG000
- value
- 196
- group Id
- BG001
- value
- 191
- group Id
- BG002
- value
- 387
- title
- PD-L1 CPS ≥1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Missing
- description
- Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Participants with a CPS ≥1 were classified as PD-L1 positive and participants with a CPS \<1 were classified as PD-L1 negative.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- PD-L1 Combined Positive Score (CPS) Status
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle